Drug Profile
IC 51
Alternative Names: IC-51; Ixiaro; Japanese-encephalitis-purified-inactivated-vaccine-Valneva; Japanese-encephalitis-vaccine-Intercell; JE-PIV; JE-PIV-Valneva; Jeev; Jespect; JEV-vaccine-Intercell; JEV-vaccine-Valneva; JevalLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator VaccGen International LLC
- Developer Adimmune Corporation; Biological E Limited; CSL; Valneva
- Class Attenuated vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Japanese encephalitis
Most Recent Events
- 09 Sep 2020 IC 51 licensed to the US Government Department of Defense in USA for prevention against Japanese encephalitis
- 01 Sep 2020 Registered for Japanese encephalitis (In infants, In children, In adolescents, Prevention) in Japan (IM) before September 2020
- 01 Sep 2020 Registered for Japanese encephalitis (In infants, In children, In adolescents, Prevention) in South Korea (IM) before September 2020